Forty Seven, Inc. to Present Initial Safety and Efficacy Data from Phase 1b Clinical Trial of 5F9 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome at 2019 ASCO Annual Meeting

World News: . []

MENLO PARK Calif May 15 2019 GLOBE NEWSWIRE -- Forty Seven Inc a clinical-stage immuno-oncology company LINK  on developing therapies to activate macrophages in the fight LINK  cancer today announced that LINK  initial data from its Ph...

More news and information about Forty Seven, Inc.

Published By:

Globe Newswire: 22:01 GMT Wednesday 15th May 2019

Published: .

Search for other references to "forty" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us